PL-3994 explained
| Width: | 300px |
| Cas Number: | 952295-80-6 |
| Pubchem: | 121488161 |
| Unii: | YI2S0GUQ2C |
| C: | 82 |
| H: | 127 |
| N: | 27 |
| O: | 20 |
| S: | 2 |
PL-3994 is an experimental bronchodilator that acts as an agonist of the natriuretic peptide receptor A. It is developed by Palatin Technologies.[1] [2]
Notes and References
- Edelson . Jeffrey D. . Makhlina . Marie . Silvester . Kevin R. . Vengurlekar . Shailesh S. . Chen . Xiaomei . Zhang . Jie . Koziol-White . Cynthia J. . Cooper . Philip R. . Hallam . Trevor J. . Hay . Douglas W.P. . Panettieri . Reynold A. . In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator . Pulmonary Pharmacology & Therapeutics . April 2013 . 26 . 2 . 229–238 . 10.1016/j.pupt.2012.11.001. 23154072 . 4070431 .
- Sica . Domenic . Jordan . Robert . Fischkoff . Steven A. . Phase IIa Study of the NPR-A Agonist, PL-3994, in Healthy Adult Volunteers with Controlled Hypertension . Journal of Cardiac Failure . August 2009 . 15 . 6 . S67 . 10.1016/j.cardfail.2009.06.207.
